Answers are grounded in this paper and cite their sources.
Background: To facilitate decisions about the possible implementation of isoniazid preventive therapy (IPT) for human immunodeficiency virus (HIV)-infected persons on a large scale, the benefits and associated costs of various policy options of IPT should be evaluated.Methods: Variable values based mainly on a prospective cohort study performed in Italy were used in an epidemiological model to assess the effects of the administration of IPT to the following groups of HIV-infected individuals: (1) tuberculin positive; (2) anergic, with various levels of immunosuppression; and (3) all HIVinfected individuals.The calculations of the costs associated with each policy option were based on the situation within the Italian national health care system.Outcome measures were average cohort survival times, total qualityadjusted life years lived in the cohort, total economic costs, and marginal costs per marginal quality-adjusted life year saved for each policy option.
No takes yet. Share an insight, caveat, or question.
Holger Sawert (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: